close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

18.23 +0.08 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 630,141
Open 18.01
Bid (Size) 18.24 (800)
Ask (Size) 19.20 (100)
Prev. Close 18.15
Today's Range 17.87 - 18.32
52wk Range 16.52 - 22.00
Shares Outstanding 65,504,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire

Performance

YTD
+4.8%
+4.8%
1 Month
+4.6%
+4.6%
3 Month
-0.1%
-0.1%
6 Month
-2.7%
-2.7%
1 Year
-6.2%
-6.2%

More News

Read More
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock
Via Benzinga
Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks
Via Chartmill
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential
Via Chartmill
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts
Via Benzinga
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday
Via Benzinga
Innoviva (INVA) Q2 Sales Jump 64%
Via The Motley Fool
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Rep. George Whitesides Has Sold Up to $5.18M Worth Of Innoviva Stock: Here's What You Should Know
Via Benzinga
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Innoviva, Inc.
Via Business Wire
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
From Innoviva, Inc.
Via Business Wire
US Stock: Innoviva
Via Talk Markets
Topics Stocks / Equities

Frequently Asked Questions

Is Innoviva, Inc. - Common Stock publicly traded?
Yes, Innoviva, Inc. - Common Stock is publicly traded.
What exchange does Innoviva, Inc. - Common Stock trade on?
Innoviva, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Innoviva, Inc. - Common Stock?
The ticker symbol for Innoviva, Inc. - Common Stock is INVA on the Nasdaq Stock Market
What is the current price of Innoviva, Inc. - Common Stock?
The current price of Innoviva, Inc. - Common Stock is 18.23
When was Innoviva, Inc. - Common Stock last traded?
The last trade of Innoviva, Inc. - Common Stock was at 11/05/25 04:00 PM ET
What is the market capitalization of Innoviva, Inc. - Common Stock?
The market capitalization of Innoviva, Inc. - Common Stock is 1.19B
How many shares of Innoviva, Inc. - Common Stock are outstanding?
Innoviva, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today